about
Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@en
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@nl
type
label
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@en
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@nl
prefLabel
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@en
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@nl
P1476
Pseudomonas aeruginosa. Vaccines and immunotherapy.
@en
P2093
Pennington JE
P304
P577
1990-06-01T00:00:00Z